Biophysical Derangements in Genetic Cardiomyopathies
- PMID: 29525644
- PMCID: PMC6204208
- DOI: 10.1016/j.hfc.2017.12.002
Biophysical Derangements in Genetic Cardiomyopathies
Abstract
This article focuses on three "bins" that comprise sets of biophysical derangements elicited by cardiomyopathy-associated mutations in the myofilament. Current therapies focus on symptom palliation and do not address the disease at its core. We and others have proposed that a more nuanced classification could lead to direct interventions based on early dysregulation changing the trajectory of disease progression in the preclinical cohort. Continued research is necessary to address the complexity of cardiomyopathic progression and develop efficacious therapeutics.
Keywords: Calcium signaling; Cardiomyopathies; Phosphorylation potential; Primary; Protein stability; Therapeutics.
Published by Elsevier Inc.
Figures




Similar articles
-
Therapeutic Strategies Targeting Inherited Cardiomyopathies.Curr Heart Fail Rep. 2017 Aug;14(4):321-330. doi: 10.1007/s11897-017-0346-8. Curr Heart Fail Rep. 2017. PMID: 28660543 Free PMC article. Review.
-
Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.Heart Fail Clin. 2018 Apr;14(2):179-188. doi: 10.1016/j.hfc.2017.12.006. Heart Fail Clin. 2018. PMID: 29525646 Free PMC article. Review.
-
Epidemiology and Clinical Aspects of Genetic Cardiomyopathies.Heart Fail Clin. 2018 Apr;14(2):119-128. doi: 10.1016/j.hfc.2017.12.007. Heart Fail Clin. 2018. PMID: 29525641 Review.
-
Genetic engineering and therapy for inherited and acquired cardiomyopathies.Ann N Y Acad Sci. 2006 Oct;1080:437-50. doi: 10.1196/annals.1380.033. Ann N Y Acad Sci. 2006. PMID: 17132800 Review.
-
Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.Circ Res. 2019 May 24;124(11):1536-1550. doi: 10.1161/CIRCRESAHA.119.313569. Circ Res. 2019. PMID: 31120825 Free PMC article. Review.
Cited by
-
A troponin T variant linked with pediatric dilated cardiomyopathy reduces the coupling of thin filament activation to myosin and calcium binding.Mol Biol Cell. 2021 Aug 19;32(18):1677-1689. doi: 10.1091/mbc.E21-02-0082. Epub 2021 Jun 23. Mol Biol Cell. 2021. PMID: 34161147 Free PMC article.
-
Complexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine.J Gen Physiol. 2021 Mar 1;153(3):e202012662. doi: 10.1085/jgp.202012662. J Gen Physiol. 2021. PMID: 33512404 Free PMC article.
-
Beyond genomics-technological advances improving the molecular characterization and precision treatment of heart failure.Heart Fail Rev. 2021 Mar;26(2):405-415. doi: 10.1007/s10741-020-10021-5. Epub 2020 Sep 3. Heart Fail Rev. 2021. PMID: 32885327 Free PMC article. Review.
-
Resolving the structure and dynamics of the disordered C terminus of human cardiac troponin T and effects of cardiomyopathic mutations.Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2425343122. doi: 10.1073/pnas.2425343122. Epub 2025 Jul 8. Proc Natl Acad Sci U S A. 2025. PMID: 40627400
-
Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy.Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17831-17840. doi: 10.1073/pnas.1910962116. Epub 2019 Aug 19. Proc Natl Acad Sci U S A. 2019. PMID: 31427533 Free PMC article.
References
-
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999–1006. - PubMed
-
- Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nature Clinical Practice Cardiovascular Medicine. 2008;5:158. - PubMed
-
- Braunwald E. Cardiomyopathies. Circulation research. 2017;121:711. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical